Compound Summary
oxidopamine
Compound Information
oxidopamine
Compound Name: | oxidopamine |
Compound CID: | 4624 |
Synonyms: | oxidopamine 6-HYDROXYDOPAMINE 1199-18-4 5-(2-aminoethyl)benzene-1,2,4-triol 6-OHDA More... |
Iupac Name: | 5-(2-aminoethyl)benzene-1,2,4-triol |
InChI: | InChI=1S/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2 |
InChIKey: | DIVDFFZHCJEHGG-UHFFFAOYSA-N |
Canonical Smiles: | C1=C(C(=CC(=C1O)O)O)CCN |
Isomeric Smiles: | C1=C(C(=CC(=C1O)O)O)CCN |
Molecular Weight: | 169.18 |
Molecular Formula: | C8H11NO3 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
oxidopamine
Molecular Weight: | 169.18 |
Molecular Formula: | C8H11NO3 |
Hydrogen Bond Donor Count: | 4 |
Hydrogen Bond Acceptor Count: | 4 |
Rotatable Bond Count: | 2 |
Heavy Atom Count: | 12 |
Complexity: | 142 |
Synonyms
oxidopamine
| oxidopamine | oxidopamine |
|---|---|
oxidopamine |
6-HYDROXYDOPAMINE |
1199-18-4 |
5-(2-aminoethyl)benzene-1,2,4-triol |
6-OHDA |
2,4,5-Trihydroxyphenethylamine |
Hydroxydopamine |
1,2,4-Benzenetriol, 5-(2-aminoethyl)- |
Oxidopamina |
Oxidopaminum |
Topamine |
5-(2-Aminoethyl)-1,2,4-benzenetriol |
UNII-8HW4YBZ748 |
8HW4YBZ748 |
CHEMBL337702 |
6-Hydroxy Dopamine hydrobromide |
CHEBI:78741 |
MLS002207128 |
Oxidopamine USAN:INN |
Oxidopaminum INN-Latin |
Oxidopamina INN-Spanish |
6-HD |
CCRIS 4342 |
SMR001306725 |
EINECS 214-842-3 |
BRN 2211011 |
5-(2-aminoethyl)benzene-1,2,4-triol;hydrobromide |
6-hydroxy-dopamine |
Spectrum_000309 |
Spectrum2_001018 |
Spectrum3_001753 |
Spectrum4_000462 |
Oxidopamine (USAN/INN) |
SCHEMBL37507 |
BSPBio_003486 |
KBioGR_000904 |
KBioSS_000789 |
4-13-00-02916 (Beilstein Handbook Reference) |
DivK1c_000362 |
SPBio_001175 |
cid_176170 |
DTXSID0036768 |
BDBM81264 |
KBio1_000362 |
KBio2_000789 |
KBio2_003357 |
KBio2_005925 |
KBio3_002706 |
ZINC39112 |
NINDS_000362 |
KUC106765N |
AKOS006230272 |
MCULE-1312792933 |
IDI1_000362 |
NCGC00167769-01 |
NCGC00167769-02 |
KSC-11-228-9 |
NCI60_001890 |
SBI-0051469.P003 |
D05294 |
AB00053512_09 |
Q780181 |
5-(2-azanylethyl)benzene-1,2,4-triol;hydrobromide |
Experimental Data
oxidopamine
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 50.000000000000000 | mM | 12.990000000000000 | 10.350000000000000 | -0.200000000000000 | 16.000000000000000 | 13.000000000000000 | -0.190000000000000 | NS | N2 | 28276260 | Inactive |
Experimental Data Visualization
oxidopamine
Statistics Data
oxidopamine
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | -0.200000000000000 | -0.190000000000000 | 1 | 1 |
Statistics Data Visualization
oxidopamine
